Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

BACKGROUND: The most recent overall survival (OS) and adverse event (AE) data have not been compared for the three guideline-recommended high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treatment alternatives. METHODS: We performed a systematic review and network meta-analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenzel, Mike, Nocera, Luigi, Collà Ruvolo, Claudia, Würnschimmel, Christoph, Tian, Zhe, Shariat, Shahrokh F., Saad, Fred, Tilki, Derya, Graefen, Markus, Kluth, Luis A., Briganti, Alberto, Mandel, Philipp, Montorsi, Francesco, Chun, Felix K. H., Karakiewicz, Pierre I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184262/
https://www.ncbi.nlm.nih.gov/pubmed/34054128
http://dx.doi.org/10.1038/s41391-021-00395-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184262/
https://www.ncbi.nlm.nih.gov/pubmed/34054128
http://dx.doi.org/10.1038/s41391-021-00395-4

Ejemplares similares